XARELTO®: Dosing for extended treatment and reduction in the risk of recurrence in deep vein thrombosis (DVT) and pulmonary embolism (PE)
Once daily for extended therapy after 6 months of initial treatment
Renal Dose Consideration*†
- Avoid using XARELTO® in patients with CrCl <15 mL/min
◇For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.
*Calculate CrCl based on actual weight.
†Patients with CrCl <30 mL/min were not studied, but administration of XARELTO® is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 mL/min to <50 mL/min).
‡The decision regarding initiation setting should be based on the prescriber's clinical judgment.
CrCl = creatinine clearance; DVT = deep vein thrombosis; PE = pulmonary embolism; VTE = venous thromboembolism.